Difluprednate and Vigamox drug interactions - a phase IV clinical study of FDA data


Drug interactions are reported among 10 people who take Difluprednate and Vigamox. Common interactions include alopecia among females, and balance disorder among males.

The phase IV clinical study analyzes what interactions people who take Difluprednate and Vigamox have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 26, 2023

10 people who take Difluprednate and Vigamox together, and have interactions are studied.

What is Difluprednate?

Difluprednate has active ingredients of difluprednate. Currently, eHealthMe is studying from 855 Difluprednate users.

What is Vigamox?

Vigamox has active ingredients of moxifloxacin hydrochloride. It is used in conjunctivitis. Currently, eHealthMe is studying from 2,802 Vigamox users.

Number of Difluprednate and Vigamox reports submitted per year:

Difluprednate and Vigamox drug interactions.

Common Difluprednate and Vigamox drug interactions by gender *:


  1. Alopecia
  2. Corneal oedema
  3. Dizziness
  4. Drug administration error
  5. Hypoacusis
  6. Back pain
  7. Blindness
  8. Blindness unilateral
  9. Cataract
  10. Corneal defect


  1. Balance disorder
  2. Arthritis
  3. Dry eye
  4. Glaucoma
  5. Headache
  6. Hepatic enzyme increased
  7. Hepatic failure
  8. Hydrocele
  9. Hyperaesthesia
  10. Memory impairment

Common Difluprednate and Vigamox drug interactions by age *:














  1. Balance disorder
  2. Cataract
  3. Confusional state
  4. Conjunctival erosion
  5. Corneal defect
  6. Corneal endothelial cell loss
  7. Corneal oedema
  8. Corneal opacity
  9. Diarrhoea
  10. Hepatic enzyme increased


  1. Dizziness
  2. Hypoacusis
  3. Dry eye
  4. Eye irritation
  5. Eye swelling
  6. Glaucoma
  7. Headache
  8. Hydrocele
  9. Hyperaesthesia
  10. Lacrimation increased

Common conditions people have *:

  1. High Blood Cholesterol: 3 people, 30.00%
  2. High Blood Pressure: 3 people, 30.00%
  3. Stress And Anxiety: 2 people, 20.00%
  4. Hair Loss: 2 people, 20.00%
  5. Multiple Allergies (allergy to multiple agents): 2 people, 20.00%
  6. Multiple Myeloma (cancer of the plasma cells): 2 people, 20.00%
  7. Nail Disorder (disease of nail): 2 people, 20.00%
  8. Bone Disorder: 2 people, 20.00%
  9. Cataract (clouding of the lens inside the eye): 2 people, 20.00%
  10. Diabetes: 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Difluprednate and Vigamox?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Browse interactions between Difluprednate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Vigamox drug interactions:

Browse interactions between Vigamox and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on difluprednate and moxifloxacin hydrochloride (the active ingredients of Difluprednate and Vigamox, respectively), and Difluprednate and Vigamox (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Difluprednate and Vigamox.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: